← Back to Search

Radiation

Perfusion Imaging for Hepatocellular Carcinoma

N/A
Waitlist Available
Led By Francois Benard, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week after cancer treatment
Awards & highlights

Study Summary

The high dose per fraction (>10Gy/fraction) used in Stereotactic Ablative Body Radiotherapy (SABR) has been shown to be more effective at local tumor control than treatments employing more conventional dose fractions. The mechanisms for this are currently under debate. One possible mechanism for this increased effectiveness is that high dose/fraction causes significant vascular damage to the tumor. This study hopes to measure vascular integrity pre and post SABR treatment using kinetic models obtained from dynamic contrast enhanced CT.

Eligible Conditions
  • Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week after cancer treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week after cancer treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in tumour vasculature as assessed by changes PL derived model parameters
Secondary outcome measures
Association (correlation) between aggregate QOL scores and PK derived model parameters

Trial Design

1Treatment groups
Experimental Treatment
Group I: Perfusion ImagingExperimental Treatment1 Intervention
IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,491 Total Patients Enrolled
2 Trials studying Hepatocellular Carcinoma
13 Patients Enrolled for Hepatocellular Carcinoma
University of British ColumbiaOTHER
1,416 Previous Clinical Trials
2,467,018 Total Patients Enrolled
1 Trials studying Hepatocellular Carcinoma
24 Patients Enrolled for Hepatocellular Carcinoma
Francois Benard, MDPrincipal InvestigatorBritish Columbia Cancer Agency
9 Previous Clinical Trials
5,034 Total Patients Enrolled
1 Trials studying Hepatocellular Carcinoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dynamic Contrast Enhanced HCC SABR Liver Study
Francois Benard 2016. "Dynamic Contrast Enhanced HCC SABR Liver Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02847767.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top